Ocata Therapeutics Inc fka OCAT

[rocky301]

bob,

(This is BS)
CHA Bio & Diostech and the U.S. firm Advanced Cell Technology recently completed a phase 3 trial of one of its three embryonic stem cell treatments using retinal pigment epithelial cells derived from human embryonic stem cells to treat blind patients with Stargardt’s Macular Dystrophy. The company announced that the trial enjoyed good results and is expecting KFDA approval in January or February.


(From CEO Rabin when asked about the above)
"As I’m sure you are well aware, CHA had nothing to do with the trials in the US. They are seeking approval to begin trials in Korea. Nothing more than that. I don’t know whether things are lost in translation or if someone is pumping up their stock or involvement in our trials. There have been frequent reports of them nearing approval to begin trials for almost one year. They aren’t near approval. We haven’t even sent them MA09 (hESC master cell lot) yet. They have to culture and manufacture their own cells, and they are not permitted to use our clinical lots of RPE. It would have to be at least 5-6 months before they could treat their first patient."